These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 3889229)

  • 1. Homoharringtonine: an effective new drug for remission induction in refractory nonlymphoblastic leukemia.
    Warrell RP; Coonley CJ; Gee TS
    J Clin Oncol; 1985 May; 3(5):617-21. PubMed ID: 3889229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial of homoharringtonine in children with refractory leukemia.
    Tan CT; Luks E; Bacha DM; Steinherz P; Steinherz L; Mondora A
    Cancer Treat Rep; 1987 Dec; 71(12):1245-8. PubMed ID: 3480043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I clinical investigation of homoharringtonine.
    Legha SS; Keating M; Picket S; Ajani JA; Ewer M; Bodey GP
    Cancer Treat Rep; 1984 Sep; 68(9):1085-91. PubMed ID: 6478448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Homoharringtonine: a phase I evaluation.
    Stewart JA; Krakoff IH
    Invest New Drugs; 1985; 3(3):279-86. PubMed ID: 4066221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I trial of homoharringtonine administered as a 5-day continuous infusion.
    Coonley CJ; Warrell RP; Young CW
    Cancer Treat Rep; 1983; 67(7-8):693-6. PubMed ID: 6871884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitoxantrone in the treatment of relapsed and refractory acute leukemia.
    Moore JO; Olsen GA
    Semin Oncol; 1984 Sep; 11(3 Suppl 1):41-6. PubMed ID: 6385265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of low-dose continuous infusion homoharringtonine in refractory acute myelogenous leukemia.
    Kantarjian HM; Keating MJ; Walters RS; Koller CA; McCredie KB; Freireich EJ
    Cancer; 1989 Mar; 63(5):813-7. PubMed ID: 2914287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continuous infusion homoharringtonine (NSC 141633) in refractory acute nonlymphocytic leukemia. An ECOG pilot study.
    Stewart JA; Cassileth PA; Bennett JM; O'Connell MJ
    Am J Clin Oncol; 1988 Dec; 11(6):627-9. PubMed ID: 3189228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II studies of homoharringtonine in patients with advanced malignant melanoma; sarcoma; and head and neck, breast, and colorectal carcinomas.
    Ajani JA; Dimery I; Chawla SP; Pinnamaneni K; Benjamin RS; Legha SS; Krakoff IH
    Cancer Treat Rep; 1986 Mar; 70(3):375-9. PubMed ID: 3955548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Homoharringtonine in patients with myelodysplastic syndrome (MDS) and MDS evolving to acute myeloid leukemia.
    Feldman EJ; Seiter KP; Ahmed T; Baskind P; Arlin ZA
    Leukemia; 1996 Jan; 10(1):40-2. PubMed ID: 8558935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Homoharringtonine in combination with cytarabine for patients with acute myelogenous leukemia.
    Feldman E; Arlin Z; Ahmed T; Mittelman A; Puccio C; Chun H; Cook P; Baskind P
    Leukemia; 1992 Nov; 6(11):1189-91. PubMed ID: 1434803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Homoharringtonine is safe and effective for patients with acute myelogenous leukemia.
    Feldman E; Arlin Z; Ahmed T; Mittelman A; Puccio C; Chun H; Cook P; Baskind P
    Leukemia; 1992 Nov; 6(11):1185-8. PubMed ID: 1434802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I and II study of fludarabine phosphate in leukemia: therapeutic efficacy with delayed central nervous system toxicity.
    Warrell RP; Berman E
    J Clin Oncol; 1986 Jan; 4(1):74-9. PubMed ID: 2416889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Homoharringtonine-induced hyperglycemia.
    Sylvester RK; Lobell M; Ogden W; Stewart JA
    J Clin Oncol; 1989 Mar; 7(3):392-5. PubMed ID: 2645387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Homoharringtonine as a new antileukemic agent.
    Ohnuma T; Holland JF
    J Clin Oncol; 1985 May; 3(5):604-6. PubMed ID: 3889228
    [No Abstract]   [Full Text] [Related]  

  • 16. Sequential homoharringtonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemia.
    O'Brien S; Kantarjian H; Koller C; Feldman E; Beran M; Andreeff M; Giralt S; Cheson B; Keating M; Freireich E; Rios MB; Talpaz M
    Blood; 1999 Jun; 93(12):4149-53. PubMed ID: 10361112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I--II evaluation of a new anthracycline antibiotic, aclacinomycin A, in adults with refractory leukemia.
    Warrell RP; Arlin ZA; Kempin SJ; Young CW
    Cancer Treat Rep; 1982 Aug; 66(8):1619-23. PubMed ID: 6955022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of homoharringtonine efficacy in the treatment of squamous cell carcinoma of the head and neck: a phase II Illinois Cancer Council Study.
    Runge-Morris MA; Kies MS; Vokes E; Blough R; Weidner L; Knop R; Rowland K
    Invest New Drugs; 1989 Jul; 7(2-3):269-73. PubMed ID: 2793384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I trial of homoharringtonine administered by prolonged continuous infusion.
    Neidhart JA; Young DC; Kraut E; Howinstein B; Metz EN
    Cancer Res; 1986 Feb; 46(2):967-9. PubMed ID: 3940656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Phase II trial of mitoxantrone in patients with relapsed and refractory acute leukemia].
    Sampi K; Kaneko Y; Maseki N; Kumai R; Sakurai M; Hattori M
    Gan To Kagaku Ryoho; 1985 Jul; 12(7):1453-7. PubMed ID: 4015120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.